Logo

Ambition at Sanger

May 17, 2010

Mike Stratton is the new director of the Wellcome Trust Sanger Institute, according to the Wellcome Trust's blog. Stratton, who studies cancer genetics, has been at Sanger since 2000 and became deputy director in 2007. "I aim to build ambitiously on the Institute's current leadership in large-scale analysis of genomes and experimental studies in model organisms to develop cellular systems that will explore human biology and to provide transformative insights into how diseases develop," Stratton says in a statement. He succeeds Allan Bradley, who left the institute in March.

Breaking News
The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.